Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | GPR68 | Q15743 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 3/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | ALPG | P10696 | 1/20 | 0.37 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14520696 | 0.69 | SLC2A1 (0.45) | PLK4NTRK1GPR68APP | |
| SCHEMBL20511162 | 0.69 | CA12 (0.50) | PLK4NTRK1GPR68PIM1 | |
| SCHEMBL17742091 | 0.69 | MAOA (0.47) | PLK4NTRK1GPR68MPOPIM1 | |
| SCHEMBL4218510 | 0.69 | CYP2D6 (0.43) | MPO | |
| SCHEMBL14818977 | 0.69 | MEN1 (0.58) | PLK4NTRK1GPR68PIM1PDE2A | |
| SCHEMBL21246205 | 0.67 | MBOAT4 (0.60) | — | |
| SCHEMBL1775955 | 0.66 | HRH4 (0.52) | — | |
| SCHEMBL853346 | 0.66 | TLR7 (0.47) | — | |
| SCHEMBL1585868 | 0.66 | KDM1A (0.44) | PIM1 | |
| SCHEMBL30724671 | 0.66 | MEN1 (0.47) | PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124645-A1 | Novel Pyrimidine-2,4-Diamine Derivatives and their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels | NEUROSEARCH A/S (DK) | 2009-05-14 | — | — | US | claimed |
| EP-1940804-A2 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NeuroSearch A/S (DK) | 2008-07-09 | — | — | EP | claimed |
| WO-2007042571-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2007-04-19 | — | — | WO | claimed |
| US-20090124645-A1 | Novel Pyrimidine-2,4-Diamine Derivatives and their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels | NEUROSEARCH A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1940804-A2 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NeuroSearch A/S (DK) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007042571-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124645-A1 | Novel Pyrimidine-2,4-Diamine Derivatives and their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels | KCNN2, KCNN1, KCNN3 | PLK4 1912/4885NTRK1 2677/4885GPR68 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.